Aradigm Corporation (OTC BB: ARDM), an emerging specialty pharmaceutical company, is committed to developing and commercializing a portfolio of drugs designed to treat severe respiratory diseases. With its clinical expertise, targeted development efforts, and strength of a well accomplished leadership team, the company is poised to capitalize on niche opportunities for new and improved products used in the treatment of severe respiratory disease. For further information, visit the Company’s web site at www.aradigm.com.
- 18 years ago
QualityStocks
Aradigm Corporation (OTC BB: ARDM)
Related Post
-
The Software Premium: How SPARC AI Is Betting That Code, Not Airframes, Decides the Next Drone War
Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid…
-
Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Leverages US Jurisdiction Advantage as Sovereign Gold Demand Reshapes Market
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid…
-
Earth Science Tech Inc. (ETST) Q1 2027 Financial and Operational Results Reflect Compounding Progress of Expansion Strategy
Earth Science Tech, a growing healthcare holding company, recently reported its Q1 2027 financial results,…